Association of doxycycline and mortality in patients hospitalized with pneumonia
Abstract
Background: Despite clinical practice guideline recommendations to use doxycycline as part of combination therapy for some patients hospitalized with pneumonia there is minimal research supporting this. Therefore, the purpose of our study was to examine the association between doxycycline use, as part of combination antibiotic therapy, and mortality for patients hospitalized with pneumonia. Methods: We identified patients > 65 years of age admitted to any US Department of Veterans Affairs hospital in fiscal years 2002-2012 with a discharge diagnosis of pneumonia. We excluded those patients who did not receive antibiotic therapy concordant with the 2019 ATS/IDSA clinical practice guidelines. Using a multilevel regression model, we examined the association of doxycycline on 30-day mortality, adjusting for demographics, comorbid conditions, severity of illness, prior outpatient medications, and admitting hospital. Results: Our cohort was comprised of 83,961 patients with a mean age of 77.8 (standard deviation 7.4) years, 98% were male, and 7.4% received doxycycline. Unadjusted mortality was 8.6% for those who received doxycycline vs. 11.7% in those who did not (p Conclusions: In this observational cohort study, we found that doxycycline use, as part of guideline-concordant antibiotic therapy, was associated with significantly lower mortality. While this supports the safety and efficacy of antibiotic regimes that include doxycycline, additional studies, especially randomized…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 83,961 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.